Cohance to Invest $10 Mn in US, Rs 230 Mn in Hyderabad Facility

18 Aug 2025 CW Team

Cohance Lifesciences, a global contract research, development, and manufacturing organisation, announced investments aimed at expanding its global capabilities across niche technology-led modalities.

The company said it will invest $10 million to enhance cGMP bioconjugation capabilities at its U.S.-based subsidiary NJ Bio. In addition, Cohance will invest Rs 230 million in a new cGMP oligonucleotide building block manufacturing facility in Hyderabad.

The US investment will support the company’s global expansion in advanced modalities, strengthening its ability to provide integrated solutions from early-stage development through late-phase clinical supply. The new cGMP bioconjugation suite at NJ Bio’s Princeton, New Jersey site will enhance the delivery of antibody-drug conjugate (ADC) solutions. Designed to handle high-potent drug substances, the suite will have the flexibility to manufacture up to 2 kg of ADCs. It is expected to be operational by the end of Q4FY26.

In Hyderabad, the upcoming facility will provide up to 700 kg annual GMP capacity for complex oligonucleotide building blocks. The company said it will help scale high-value chemistries from laboratory to commercial manufacturing, catering to the growing demand for oligonucleotide-based therapeutics.

Customer engagements are underway, with audits scheduled in the coming quarters. Kilo lab validations and modified nucleotide work are ongoing, with GMP-grade PMO and LNA amidite validations set to begin by December.

Cohance said the two investments are part of its capacity expansion programme in high-growth areas, aimed at supporting innovators globally from early development through commercial supply.

News source: The Hindu

Infrastructure Urban

10 Sep 2025

India Achieves TEC Certification for Indigenous Telecom System

India’s semiconductor ambitions received a major boost as a telecom system built with indigenously manufactured chips secured Telecommunication Engineering Center (TEC) certification.Union IT Minister Ashwini Vaishnaw announced the achievement on X, calling it a “big leap for India’s semiconductor story.” For the first time, a telecom system powered by Indian-made chips has successfully cleared all standards and quality tests.TEC certification, issued by the Department of Telecommunications, confirms that the product meets stringent benchmarks for performance and quality. This mileston..

Mumbai Metro Line 4 Trial Runs Set to Begin This Month

Trial runs on Mumbai Metro Line 4 are expected to commence this month, with passenger services on its initial phase likely to start by the end of 2025. The Green Line will operate between Kasarvadavali and Wadala, covering 32.3 km with 32 stations, providing much-needed relief to commuters in eastern and central Mumbai and Thane.Mumbai Metropolitan Region Development Authority (MMRDA) officials stated that work is advancing rapidly on a 10.5-km section between Gaimukh and Cadbury Junction, which includes 10 stations. This stretch will open first, followed by the remainder of the line.Approxima..

Mumbai Metro Line 11 Approved, Extending Corridor to Gateway

The Maharashtra Cabinet has approved the Mumbai Metro Line 11 project, extending Line 4 along the Wadala–Thane–Kasarvadavli route to the Gateway of India. The 17.5 km corridor, comprising 13 km underground and 4.3 km elevated sections, is estimated to cost Rs 23,488 crore and will feature 14 stations. The Mumbai Metropolitan Region Development Authority (MMRDA) will implement the project, with central government support provided through equity and interest-free subordinate debt, while the state government will manage the loan component.The original alignment from Wadala to CSMT, which trav..